ATE522513T1 - N-phenylarylsulfonamidverbindung, arzneimittel das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellung - Google Patents
N-phenylarylsulfonamidverbindung, arzneimittel das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellungInfo
- Publication number
- ATE522513T1 ATE522513T1 AT05109059T AT05109059T ATE522513T1 AT E522513 T1 ATE522513 T1 AT E522513T1 AT 05109059 T AT05109059 T AT 05109059T AT 05109059 T AT05109059 T AT 05109059T AT E522513 T1 ATE522513 T1 AT E522513T1
- Authority
- AT
- Austria
- Prior art keywords
- compound
- methyl
- production
- active ingredient
- phenylarylsulfonamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001068498 | 2001-03-12 | ||
| JP2001281569 | 2001-09-17 | ||
| JP2002007760 | 2002-01-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE522513T1 true ATE522513T1 (de) | 2011-09-15 |
Family
ID=27346214
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05109059T ATE522513T1 (de) | 2001-03-12 | 2002-03-11 | N-phenylarylsulfonamidverbindung, arzneimittel das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellung |
| AT02705096T ATE362924T1 (de) | 2001-03-12 | 2002-03-11 | N-phenylarylsulfonamidverbindung, arzneimittel, das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellung |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02705096T ATE362924T1 (de) | 2001-03-12 | 2002-03-11 | N-phenylarylsulfonamidverbindung, arzneimittel, das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellung |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US7235667B2 (enExample) |
| EP (2) | EP1612208B1 (enExample) |
| JP (3) | JP3555620B2 (enExample) |
| KR (1) | KR100886854B1 (enExample) |
| CN (1) | CN1294126C (enExample) |
| AT (2) | ATE522513T1 (enExample) |
| AU (1) | AU2002238855B2 (enExample) |
| BR (1) | BR0208027A (enExample) |
| CA (1) | CA2439604C (enExample) |
| CZ (1) | CZ304035B6 (enExample) |
| DE (1) | DE60220255T2 (enExample) |
| DK (2) | DK1369419T3 (enExample) |
| ES (1) | ES2286230T3 (enExample) |
| HU (1) | HU230056B1 (enExample) |
| IL (2) | IL157701A0 (enExample) |
| MX (1) | MXPA03008134A (enExample) |
| NO (1) | NO329682B1 (enExample) |
| NZ (1) | NZ528120A (enExample) |
| PL (1) | PL218750B1 (enExample) |
| PT (2) | PT1612208E (enExample) |
| RU (1) | RU2299202C2 (enExample) |
| TW (1) | TWI317359B (enExample) |
| WO (1) | WO2002072564A1 (enExample) |
| ZA (1) | ZA200306884B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2004022549A1 (ja) * | 2002-09-09 | 2005-12-22 | 小野薬品工業株式会社 | ４−メチル−１，３−チアゾール−２−イルスルホニルハライドの製造方法 |
| CN100408570C (zh) * | 2003-01-29 | 2008-08-06 | 阿斯特兰德英国有限公司 | Ep4受体拮抗剂 |
| GB0317500D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Treatment of bph |
| WO2005000356A1 (ja) * | 2003-06-27 | 2005-01-06 | Ono Pharmaceutical Co., Ltd. | 尿路疾患治療剤 |
| GB0401334D0 (en) * | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| US20080033018A1 (en) * | 2004-07-05 | 2008-02-07 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic Agents For Overactive Bladder |
| JP2008189549A (ja) * | 2005-05-12 | 2008-08-21 | Astellas Pharma Inc | カルボン酸誘導体またはその塩 |
| JP2009057282A (ja) * | 2005-12-19 | 2009-03-19 | Astellas Pharma Inc | カルボン酸誘導体又はその塩 |
| TW200817319A (en) | 2006-08-10 | 2008-04-16 | Astellas Pharma Inc | Sulfonamide compound or salt thereof |
| BRPI0807942A2 (pt) * | 2007-02-16 | 2014-07-01 | Ono Pharmaceutical Co | Agente terapêutico para distúrbio de excreção urinária |
| ATE554070T1 (de) * | 2007-08-01 | 2012-05-15 | Taisho Pharmaceutical Co Ltd | Hemmer der s1p1-bindung |
| SG157299A1 (en) | 2008-05-09 | 2009-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
| CN102076660B (zh) * | 2008-06-23 | 2014-01-08 | 安斯泰来制药有限公司 | 磺胺化合物或其盐 |
| TW201107309A (en) * | 2009-07-27 | 2011-03-01 | Kissei Pharmaceutical | Indole derivatives, or the pharmaceutically acceptable salts |
| CN103209960A (zh) * | 2010-07-26 | 2013-07-17 | 百时美施贵宝公司 | 用作cyp17抑制剂的磺酰胺化合物 |
| JP5363636B2 (ja) * | 2011-10-21 | 2013-12-11 | ファイザー・リミテッド | 新規な塩および医学的使用 |
| US20140039004A1 (en) * | 2012-07-31 | 2014-02-06 | Ono Pharmaceutical Co., Ltd. | Method of treating of gastroesophageal reflux disease |
| CN106660063B (zh) * | 2014-04-30 | 2019-06-18 | 佩纳尔维工业有限公司 | 用于将液体应用于不同形状的盖子上的可编程同心头 |
| SG11201803867TA (en) * | 2015-11-13 | 2018-06-28 | Daewoong Pharmaceutical Co Ltd | Sodium channel blocker |
| RU2659955C1 (ru) * | 2017-10-26 | 2018-07-04 | Галина Ильхамовна Лукина | Способ диагностики высоких гастроэзофагеальных рефлюксов |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2419923A1 (de) * | 1973-04-28 | 1974-11-28 | Fujisawa Pharmaceutical Co | Sulfonsaeureester, verfahren zu deren herstellung und verwendung derselben als kondensationsmittel |
| JPS5748534B2 (enExample) | 1974-03-04 | 1982-10-16 | ||
| DE2555048A1 (de) * | 1975-12-06 | 1977-06-30 | Pfersee Chem Fab | Verfahren und vorrichtung zur herstellung bestaendiger, waessriger emulsionen wasserunloeslicher substanzen |
| JPS5293469A (en) | 1976-02-02 | 1977-08-05 | Fuji Photo Film Co Ltd | Method of curing gelatin |
| JPH05293469A (ja) | 1992-04-17 | 1993-11-09 | Toda Constr Co Ltd | 滅菌精製水の製造方法およびその装置 |
| NZ247440A (en) * | 1992-05-06 | 1995-04-27 | Squibb & Sons Inc | Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof |
| TW523506B (en) | 1996-12-18 | 2003-03-11 | Ono Pharmaceutical Co | Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients |
| WO2000069465A1 (en) * | 1999-05-12 | 2000-11-23 | Ono Pharmaceutical Co., Ltd. | Anticancer agents containing ep1 antagonists as the active ingredient |
| WO2001008674A1 (en) | 1999-07-29 | 2001-02-08 | Ono Pharmaceutical Co., Ltd. | Sulfonamide derivatives and remedies for allodynia |
| US7335776B2 (en) * | 2001-03-14 | 2008-02-26 | Ono Pharmaceutical Co., Ltd. | Remedies for depression containing EP1 antagonist as the active ingredient |
-
2002
- 2002-03-11 JP JP2002571480A patent/JP3555620B2/ja not_active Expired - Fee Related
- 2002-03-11 DE DE60220255T patent/DE60220255T2/de not_active Expired - Lifetime
- 2002-03-11 EP EP05109059A patent/EP1612208B1/en not_active Expired - Lifetime
- 2002-03-11 PT PT05109059T patent/PT1612208E/pt unknown
- 2002-03-11 EP EP02705096A patent/EP1369419B1/en not_active Expired - Lifetime
- 2002-03-11 CA CA2439604A patent/CA2439604C/en not_active Expired - Fee Related
- 2002-03-11 CZ CZ20032452A patent/CZ304035B6/cs not_active IP Right Cessation
- 2002-03-11 DK DK02705096T patent/DK1369419T3/da active
- 2002-03-11 KR KR1020037011921A patent/KR100886854B1/ko not_active Expired - Fee Related
- 2002-03-11 PT PT02705096T patent/PT1369419E/pt unknown
- 2002-03-11 MX MXPA03008134A patent/MXPA03008134A/es active IP Right Grant
- 2002-03-11 BR BR0208027-3A patent/BR0208027A/pt not_active IP Right Cessation
- 2002-03-11 PL PL365100A patent/PL218750B1/pl unknown
- 2002-03-11 RU RU2003127677/04A patent/RU2299202C2/ru not_active IP Right Cessation
- 2002-03-11 AT AT05109059T patent/ATE522513T1/de active
- 2002-03-11 TW TW091104451A patent/TWI317359B/zh not_active IP Right Cessation
- 2002-03-11 NZ NZ528120A patent/NZ528120A/en not_active IP Right Cessation
- 2002-03-11 ES ES02705096T patent/ES2286230T3/es not_active Expired - Lifetime
- 2002-03-11 DK DK05109059.5T patent/DK1612208T3/da active
- 2002-03-11 IL IL15770102A patent/IL157701A0/xx unknown
- 2002-03-11 AU AU2002238855A patent/AU2002238855B2/en not_active Ceased
- 2002-03-11 WO PCT/JP2002/002245 patent/WO2002072564A1/ja not_active Ceased
- 2002-03-11 AT AT02705096T patent/ATE362924T1/de active
- 2002-03-11 HU HU0400155A patent/HU230056B1/hu not_active IP Right Cessation
- 2002-03-11 US US10/471,673 patent/US7235667B2/en not_active Expired - Fee Related
- 2002-03-11 CN CNB028097904A patent/CN1294126C/zh not_active Expired - Fee Related
-
2003
- 2003-09-02 IL IL157701A patent/IL157701A/en not_active IP Right Cessation
- 2003-09-03 ZA ZA2003/06884A patent/ZA200306884B/en unknown
- 2003-09-10 NO NO20034007A patent/NO329682B1/no not_active IP Right Cessation
- 2003-12-24 JP JP2003427226A patent/JP3741120B2/ja not_active Expired - Fee Related
-
2005
- 2005-08-26 JP JP2005245763A patent/JP4432051B2/ja not_active Expired - Fee Related
- 2005-09-30 US US11/239,406 patent/US7629369B2/en not_active Expired - Fee Related
-
2009
- 2009-10-21 US US12/603,194 patent/US8088802B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE362924T1 (de) | N-phenylarylsulfonamidverbindung, arzneimittel, das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellung | |
| DE60018064D1 (de) | Substituierte phenylpropionsäurederivate als agonisten des menschlichen peroxisom-proliferator-aktiverten rezeptors alpha(ppar) | |
| MY143051A (en) | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes | |
| NZ514661A (en) | alpha-substituted carboxylic acid derivatives and their use as therapeutic agents in pharmaceutical compositions | |
| GEP20084325B (en) | Purine compounds and uses thereof as cannabinoid receptor ligandspurine compounds and uses thereof as cannabinoid receptor ligands | |
| BR0014679A (pt) | 2-tio-3,5-diciano-4-aril-6-aminopiridinas substituìdas e sua aplicação | |
| ES2195943T3 (es) | Compuestos heteroaromaticos biciclicos y triciclicos. | |
| DE60021113T2 (de) | Albumin-bindende verbindungen die die nichtenzymatische glycosylierung verhindern und die zur behandlung von glycosylierungsbedingten erkrankungen verwendet werden können | |
| DE60039878D1 (de) | XENON ALS NMDA-ANTOGONIST zur Neuroprotektion | |
| HK1046405A1 (zh) | 作为nmda受体拮抗剂用於治疗疼痛的取代的1，5-二氢吡咯-2-酮衍生物 | |
| ATE246180T1 (de) | Benzofuranon-derivate und verfahren zu ihrer herstellung | |
| DE59905075D1 (de) | S-substituierte 11beta-benzaldoxim-estra-4,9-dien-kohlensäurethiolester, verfahren zu deren herstellung und diese verbindungen enthaltene pharmazeutische zubereitungen | |
| WO2007127421A3 (en) | Process for the synthesis of (+) and (-)-1-aryl-3-azabicyclo[3.1.0]hexanes | |
| JPS58159489A (ja) | ２，３−ジアリ−ル−５−ハロチオフエン化合物 | |
| WO2003018010A1 (en) | Preventive and/or remedial agent for disease attributable to arteriosclerotic activity | |
| Breining et al. | Neuronal nicotinic acetylcholine receptor modulators: recent advances and therapeutic potential | |
| WO2001082858A2 (de) | Neue verbindungen zur behandlung inflammatorischer und kardiovaskulärer erkrankungen | |
| DE50006842D1 (de) | 4-benzylaminochinoline konjugate mit gallensaeure und ihre heteroanalogen, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und deren anwendung | |
| JP5439817B2 (ja) | 尿排出障害治療剤 | |
| WO2002044130A1 (fr) | Dérivés d'acide carboxylique substitués | |
| JPWO2001032164A1 (ja) | ２０−ｈｅｔｅ産生酵素阻害剤 | |
| EP1869004A4 (en) | SUBSTITUTED CARBOXYLENE DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPIDES, THEIR PREPARATION AND APPLICATION | |
| ATE247963T1 (de) | Medikament zur behandlung von glaukoma und ischämischer retinopathie | |
| CA3305394A1 (en) | Irak degradation agent and use thereof | |
| RU96119347A (ru) | 2-(4-метоксифенокси)-3-аминопиридин, его получение и применение в качестве противовоспалительного агента |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1612208 Country of ref document: EP |